ReviewNature reviews. Rheumatology2024
Update on the pathophysiology and treatment of primary Sjögren syndrome.
Review in Nature reviews. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Familial and genetic overlap between Sjögren's disease and other autoimmune diseases.Frontiers in immunology · 2026Pooled it
- Comparative efficacy and safety of topical therapies for ocular involvement in Sjögren's syndrome: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Network meta-analysis of integrated traditional Chinese and Western medicine in the treatment of Sjogren's syndrome.Frontiers in pharmacology · 2024Pooled it
- Laser Acupuncture on the Management of Xerostomia in Sjögren's Disease: A Randomized Clinical Trial.Oral diseases · 2026Trial
- Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial.RMD open · 2025Trial
- Mendelian randomization and single-cell transcriptomics prioritize CD7 and LAPTM5 in primary Sjögren's disease: an integrative multi-omics analysis.Clinical rheumatology · 2026Article
- Risk of cognitive disorders in patients with primary Sjögren's disease: data from Korean Health Insurance Service.RMD open · 2026Article
- Phloretin Modulates STING Ubiquitination Degradation to Restrain Dendritic Cell Overactivation and Alleviate Sjögren's Syndrome.Pharmaceuticals (Basel, Switzerland) · 2026Article
- [Pathophysiological aspects of primary Sjögren's disease : From epithelial activation to systemic autoimmunity].Zeitschrift fur Rheumatologie · 2026Review
- Clinical and Ultrasonographic Characterization of Proposed Sjögren's Disease Phenotypes in a Korean Longitudinal Cohort.Journal of clinical medicine · 2026Article
- Effect of JAK Inhibitors on Fatigue and Sleep Quality in Patients with Rheumatoid Arthritis: A Narrative Review.Journal of clinical medicine · 2026Review
- Low albumin-to-globulin ratio is associated with interstitial lung disease in primary Sjögren's syndrome: a single-center retrospective cohort study with propensity score matching.Rheumatology international · 2026Article
- PDE4D-CXCL13 axis in gland epithelial cells promotes B cell infiltration in primary Sjögren's syndrome.Acta pharmacologica Sinica · 2026Article
- IFI6 is associated with interferon activation and complement-associated immune responses in primary Sjögren's disease.Functional & integrative genomics · 2026Article
- Construction of a nomogram for anxiety and depression in patients with Sjögren's syndrome by combining tongue and pulse characteristics: a cross-sectional study based on a prospective cohort.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Fatigue in Sjögren's Disease - Integrating Biomedical and Psychosocial Aspects: A Narrative Review.Rheumatology and therapy · 2026Review
- Serum exosomal tRNA-derived small RNAs as diagnostic biomarkers for primary Sjögren's syndrome: a combined model with autoantibodies.Clinical rheumatology · 2026Article
- Agomelatine for Sjögren's syndrome: a study on its therapeutic effects and mechanisms.Inflammopharmacology · 2026Article
- Assessment of salivary gland involvement in primary Sjögren's syndrome using ultrasound viscoelasticity imaging.European radiology · 2026Article
- Single-Cell RNA Sequencing Revealed the Role of Interferon-Gamma Related Genes in Primary Sjögren's Syndrome.Journal of cellular and molecular medicine · 2026Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia. Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma. Sjögren syndrome is therefore a complex and disabling disease associated with a reduced quality of life and with considerable long-term damage. Most of the available treatments are merely symptomatic with limited efficacy in both preventing glandular damage and suppressing systemic disease activity. In the past 10 years, great progress has been made in understanding the pathophysiology of Sjögren syndrome, opening new avenues towards a more targeted and individualized therapeutic approach to the disease. Indeed, several randomized controlled trials have just been completed or are poised to commence evaluating the effectiveness of novel drugs targeting both innate and adaptive immune pathways, including pro-inflammatory cytokines, the type I interferon system, B cell activation, B cell and T cell co-stimulation pathway, and ectopic germinal centre formation. Novel clinical trials are also ongoing exploring various targeted approaches (that is, IgG recycling inhibition, nuclease therapy and CAR-T cell therapy) for Sjögren syndrome.
Indexed as
Identifiers
38982205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.